Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Neoplasms 7Leukemia, Myeloid, Acute 6Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Neoplasm Metastasis 4Carcinoma, Transitional Cell 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Melanoma 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Urinary Bladder Neoplasms 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Lymphoma, B-Cell 2Lymphoma 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Colonic Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × ALT-803 × Clear all
NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

ImmunityBio, Inc.

Phase 1/2 Active not recruiting
369 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

ImmunityBio, Inc.

Phase 2/3 Active not recruiting
190 enrolled 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡